SEC Filing Analysis: ZimVie Inc. (ZIMV)

Executive Summary

• Trading Significance: High
• Key Takeaway: ZimVie Inc. has completed its merger with an affiliate of the investment firm ARCHIMED, resulting in the company being taken private and its stock delisted from NASDAQ.
• Market Impact: This is a terminal event for public shareholders of ZIMV, who will receive $19.00 in cash for each share. The stock will cease trading.

Company Information

Field	Value
Company	ZimVie Inc.
Ticker Symbol	ZIMV
CIK	0001876588
Industry	Dental Equipment & Supplies

Insider Information

Field	Value
Name	null
CIK	null
Title/Position	null
Relationship	This filing reports a corporate change of control, not an individual insider transaction.

Transaction Details

Field	Value
Form Type	8-K
Transaction Date	2025-10-20
Transaction Code	M (Merger)
Security Type	Common Stock
Shares Involved	28,200,000
Price Per Share	$19.00
Total Value	$535,800,000
Shares Owned After	0 (by public shareholders)
Ownership Type	Not Applicable

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$535,800,000
% of Market Cap	101.09%
Shares Transacted	28,200,000
% of Shares Outstanding	100.0%
Post-Transaction Ownership	0 shares (0% of outstanding)
Materiality Assessment	Highly Significant

Impact Evaluation

• Market Cap Context: The acquisition of the entire company for $535.8M is the ultimate material event, exceeding its $530M market capitalization and realizing the full value for shareholders in cash.
• Ownership Concentration: Ownership is being fully consolidated under the private acquirer, ARCHIMED. Public float will be eliminated.
• Dilution Impact: Not applicable. This transaction cashes out all existing equity, including RSUs, Options, and DSUs, as detailed in the filing.
• Transaction Significance: As a 100% acquisition of all outstanding shares, this transaction's significance is absolute. It represents a complete change of control and the end of ZimVie's status as a publicly-traded entity.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral/Final
• Reasoning: The stock will be delisted. The price is now fixed at the $19.00 per share merger consideration. There is no further market action for ZIMV common stock.

Volume & Sentiment

• Expected Volume Impact: Trading will be suspended and then cease entirely.
• Sentiment Indicator: Bearish for the stock's existence, but the cash-out at a premium is a defined positive outcome for shareholders who held through the acquisition.

Investment Insights

Positive Market Indicators

• Shareholders receive a cash payout, providing liquidity and a realized gain/loss.
• The acquisition price of $19.00 per share represents the final value for shareholders.

Risk Factors

• The primary 'risk' is the opportunity cost, as shareholders will no longer participate in any future upside of the company, which is now private.

Key Takeaways

1. Company Goes Private: ZimVie Inc. is no longer a public company and is now a wholly owned subsidiary of Zamboni Parent Inc. (an ARCHIMED affiliate).
2. Cash Payout: All holders of Common Stock, RSUs, Options (in-the-money), and DSUs will be cashed out at $19.00 per share (or the equivalent for derivatives).
3. Delisting from NASDAQ: The company has notified NASDAQ to suspend trading and delist the ZIMV ticker symbol.

Additional Context

Transaction Notes

• Timing: The merger was consummated on October 20, 2025, following an agreement announced on July 20, 2025.
• Special Circumstances: As part of the merger, the company's board of directors and executive officers have resigned, and new directors and officers appointed by the acquirer have taken their place.
• Market Environment: This take-private transaction occurs in the healthcare sector, where private equity firms like ARCHIMED actively seek to acquire and grow specialized companies outside the pressures of public markets.